| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/18/2001 | CA2383496A1 Compounds for treatment of infectious and immune system disorders and methods for their use |
| 01/18/2001 | CA2381125A1 Ligands for use in therapeutic compositions for the treatment of hemostasis disorders |
| 01/18/2001 | CA2379373A1 Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins |
| 01/18/2001 | CA2379362A1 Respiratory syncytial viruses expressing immune modulatory molecules |
| 01/18/2001 | CA2379345A1 T-cell receptor .gamma. alternate reading frame protein, (tarp) and uses thereof |
| 01/18/2001 | CA2379274A1 Blocking immune response to a foreign antigen using an antagonist which binds to cd20 |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2379059A1 Mosaic infectious bursal disease virus vaccines |
| 01/18/2001 | CA2379012A1 In vitro reconstitution of segmented negative-strand rna viruses |
| 01/18/2001 | CA2379010A1 Methods of inducing cell death |
| 01/18/2001 | CA2378875A1 Novel neisseria meningitidis compounds and anti-infection applications thereof |
| 01/18/2001 | CA2378846A1 Prostase vaccine |
| 01/18/2001 | CA2378763A1 Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosis esat-6 gene family |
| 01/18/2001 | CA2378661A1 Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines |
| 01/18/2001 | CA2378600A1 Amino ceramide-like compounds and therapeutic methods of use |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/18/2001 | CA2378552A1 Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines |
| 01/18/2001 | CA2378515A1 Compositions corresponding to a calcium transporter and methods of making and using same |
| 01/18/2001 | CA2378451A1 Anti-idiotypic antibodies of fibroblast growth factors and their use as medicines |
| 01/18/2001 | CA2378407A1 Dna coding for beta-tubulin and use thereof |
| 01/18/2001 | CA2378240A1 Gamma-herpesvirus dna and methods of use |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | CA2377674A1 Novel methods and medicament for treating infectious diseases involving microbial biofilms |
| 01/18/2001 | CA2373534A1 Donor strand complemented pilin and adhesin broad-based vaccines |
| 01/17/2001 | EP1069187A1 Mosaic Infectious Bursal Disease Virus vaccines |
| 01/17/2001 | EP1069182A1 Alleviation of symptoms associated with inflammatory disease states, using antibodies to CD18 |
| 01/17/2001 | EP1069133A1 Neisseria meningitidis compounds and anti-infection applications thereof |
| 01/17/2001 | EP1068871A1 Novel methods and medicament for treating infections diseases involving microbial biofilms |
| 01/17/2001 | EP1068799A2 Biological models capable of exhibiting secondary disease manifestations |
| 01/17/2001 | EP1068522A1 Antigen |
| 01/17/2001 | EP1068362A1 Hepatitis c virus ns5b compositions and methods of use thereof |
| 01/17/2001 | EP1068357A1 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
| 01/17/2001 | EP1068331A1 Medicaments for inducing cytotoxic t-cells |
| 01/17/2001 | EP1068329A2 FUSION PROTEINS OF $i(MYCOBACTERIUM TUBERCULOSIS) ANTIGENS AND THEIR USES |
| 01/17/2001 | EP1068328A1 Treatment and diagnosis of staphylococcal infections |
| 01/17/2001 | EP1068327A2 DNA IMMUNIZATION AGAINST $i(CHLAMYDIA) INFECTION |
| 01/17/2001 | EP1068323A2 Recombinant major allergen of the pollen of artemisia vulgaris (mugwort) |
| 01/17/2001 | EP1068318A2 Human nucleic acid sequences from prostate tissue |
| 01/17/2001 | EP1068300A1 Suppressive monocyte derived cells, process for their preparation and their uses in pharmaceutical compositions |
| 01/17/2001 | EP1068297A1 Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency |
| 01/17/2001 | EP1068296A1 Methods and compositions for eliciting an immune response to a telomerase antigen |
| 01/17/2001 | EP1068293A1 Vaccination modalities |
| 01/17/2001 | EP1068235A1 G-protein coupled receptors |
| 01/17/2001 | EP1068229A1 Peptides |
| 01/17/2001 | EP1068226A1 Lipopeptides inducing t lymphocytic cytotoxicity bearing at least one auxiliary t epitope, and uses for vaccination |
| 01/17/2001 | EP1068220A1 nrdF |
| 01/17/2001 | EP1067964A1 Immunomodulatory compositions of mmtv antigens and methods of using same |
| 01/17/2001 | EP1067963A1 Hiv-specific cytotoxic t-cell responses |
| 01/17/2001 | EP1067962A2 Derivatives of pneumococcal choline binding proteins for vaccines |
| 01/17/2001 | EP1067961A2 Leishmania cysteine proteinases |
| 01/17/2001 | EP1067960A2 A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient |
| 01/17/2001 | EP1067956A2 Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| 01/17/2001 | EP1067954A1 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE |
| 01/17/2001 | EP1067953A1 Methods for treating an ischemic disorder and improving stroke outcome |
| 01/17/2001 | EP1067944A1 New combined preparation for the treatment of neoplasic diseases or of infectious diseases |
| 01/17/2001 | EP1067940A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 01/17/2001 | EP0771216B1 Methods and compositions for the specific coagulation of tumoral vasculature |
| 01/17/2001 | EP0750514B1 Immunotherapeutic preparations containing gamma globulins for treating cancerous diseases |
| 01/17/2001 | EP0589982B1 Monoclonal antibodies against human tnf-binding protein i (tnf-bp i) |
| 01/17/2001 | CN1280620A Antigen protein and nucleic acid coding for said protein |
| 01/17/2001 | CN1280619A (Chlamydia trachomatic) genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
| 01/17/2001 | CN1280611A Method and compositions for binding hematopoietic stem cells |
| 01/17/2001 | CN1280504A Vaccines with an LTB adjuvant |
| 01/17/2001 | CN1280011A Double expression process of producing hepatitis B virus vaccine |
| 01/17/2001 | CN1060804C IV collagen enzyme specific antibody for human gene engineering |
| 01/16/2001 | US6174995 Amino acid sequences of chemokine beta-4 and monocyte chemotactic protein-4; anticarcinogenic/antitumor agents; antifibrotic/antiarthritic/antiinflammatory agents; treatment of chronic infections, autoimmune disorders, psoriasis |
| 01/16/2001 | US6174994 7TM receptor (H2CAA71) |
| 01/16/2001 | US6174916 Methods for treating herpes virus infections |
| 01/16/2001 | US6174872 Immunotherapy of allergic asthma in both its early and late stages by administering to the mucosa a polynucleotide encoding an asthma-initiating antigen and immunostimulatory neucleotide seqence stimulating the th1 lymhocytes |
| 01/16/2001 | US6174721 Protein having kunitz-type domains of tissue factor pathway inhibitors and lacking glycosylation sites; for prevention and treatment of septic shock |
| 01/16/2001 | US6174714 Lyss |
| 01/16/2001 | US6174703 Nucleotide sequences coding a polymerase binding protein; for the treatment of cancer, acquired immune deficiency syndrome, aging and cell proliferative defects |
| 01/16/2001 | US6174700 Purification of a polypeptide compound having a polysaccharide binding domain by affinity phase separation |
| 01/16/2001 | US6174692 Detecting preferential antigen in sample; incubating monoclonal antibody with sample containing preferential antigen and detecting biinding |
| 01/16/2001 | US6174691 Deactivating a preferential tumor glycoprotein or a cell expressing preferential glycoprotein; exposing preferential glycoprotein or cell expressing the preferential glycoprotein to a toxic substance |
| 01/16/2001 | US6174685 Human herpesvirus type 6 protein p100, the corresponding DNA sequences, their preparation and use |
| 01/16/2001 | US6174666 Reducing adjustments in ribonucleic acid sequences; providing gene coding transcription products, detect regulatory sequences, insert point mutations, transfect mutated gene into cells, culture cells and monitoring gene expression |
| 01/16/2001 | US6174539 Localized use of nitric oxide adducts to prevent internal tissue damage |
| 01/16/2001 | US6174532 L2 immunogenic peptides of papillomavirus |
| 01/16/2001 | US6174529 Oral therapy for the treatment of allergies and method of manufacture |
| 01/16/2001 | US6174528 Inducing protective antibodies against group a streptococci |
| 01/16/2001 | CA2313899A1 Novel selective imune down regulation (sidr) mediated transplantation processes, processes for preventing or treating diseases in a subject, and compositions of matter comprising trained or programmed cells, tissues or organs useful for sidr establishment |
| 01/16/2001 | CA2029861C Diagnosis and treatment of insulin dependent diabetes mellitus |
| 01/16/2001 | CA2010800C Protein labelling |
| 01/16/2001 | CA1341166C Antigenic proteins and vaccines containing them for prevention of coccidiosis |
| 01/11/2001 | WO2001002607A1 Adenovirus carrying gag gene hiv vaccine |
| 01/11/2001 | WO2001002594A2 DNA CONSTRUCTS BASED ON THE eIF4A GENE PROMOTER |
| 01/11/2001 | WO2001002587A2 Novel antifungal agents and fungicides, method for the production thereof and their use |
| 01/11/2001 | WO2001002577A1 Pseudomonas aeruginosa antigens |
| 01/11/2001 | WO2001002575A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 01/11/2001 | WO2001002557A1 Neurotrophic factor receptor |
| 01/11/2001 | WO2001002550A2 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | WO2001002440A1 Fusion peptides comprising a peptide ligand domain and a multimerization domain |
| 01/11/2001 | WO2001002439A1 Neovascular-targeted immunoconjugates |
| 01/11/2001 | WO2001002018A2 Compounds that associate on the intermolecular level and aggregate bodies that contain them |
| 01/11/2001 | WO2001002011A1 REMEDIES FOR DISEASES CAUSED BY PTH OR PTHrP |
| 01/11/2001 | WO2001002009A1 Method and composition for inhibition of vasospasm |
| 01/11/2001 | WO2001002008A1 Control of acidosis |
| 01/11/2001 | WO2001002007A1 Method for enhancing an immune response |
| 01/11/2001 | WO2000066739A3 Chlamydia antigens and corresponding dna fragments and uses thereof |